CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.
about
Clinically relevant genetic variants of drug-metabolizing enzyme and transporter genes detected in Thai children and adolescents with autism spectrum disorder.Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain.Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study.Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high HIV and tuberculosis burden countries: a systematic review.Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype
P2860
Q36808178-F5EC9BE5-FCD2-4A59-B7BB-30D5B3D5C148Q38755666-AF858961-6787-44B0-A505-29675D5CC968Q38855121-F897F984-0E62-4BF5-90FD-A688C15E6AF7Q39039468-CF2E478E-2F67-486D-8C15-A7F70741E8B9Q39944445-C83FA020-334C-45EF-8E0F-70035934498CQ40563423-A0D71DA0-4830-43C7-A911-03F60B0A0916Q40694902-8F4892EC-57BB-463C-BDC0-4A34C16A9670Q41240864-4C0CF0C2-17E9-4F85-84B8-D9C992A28BF0Q52330065-1BB43C90-3D70-4503-AC9D-1E8966284682Q58612379-8058DFA0-7DC8-4772-860E-033386FE0DA2
P2860
CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
CYP2B6 genotype, but not rifam ...... erm efavirenz plasma exposure.
@en
type
label
CYP2B6 genotype, but not rifam ...... erm efavirenz plasma exposure.
@en
prefLabel
CYP2B6 genotype, but not rifam ...... erm efavirenz plasma exposure.
@en
P2093
P2860
P356
P1433
P1476
CYP2B6 genotype, but not rifam ...... erm efavirenz plasma exposure.
@en
P2093
Jackson K Mukonzo
Jasper Ogwal-Okeng
Paul Waako
Sarah Nanzigu
P2860
P304
P356
10.2217/PGS.14.73
P577
2014-08-01T00:00:00Z